麻豆传媒

Transformation occurs in a minority of patients, with an extremely poor prognosis

Momentum grows for earlier intervention, including pre-fibrotic disease

Other JAK inhibitors, combinations, and novel therapies offer more hope for patients

The procedure offers a potential cure, but comes with a risk of early morbidity and mortality

Genetics already informs prognosis, may help guide therapy development beyond JAK2 inhibition

Increased interest follows mutation discoveries, development of targeted therapies